Use of a new, fexible lipidocolloid dressing on acute and chronic wounds: results of a clinical study

Abstract

This evaluation was sponsored by Laboratoires URGO, Chenôve, France.

The Effect of Burns & Wounds (B&W)/Burdock Leaf Therapy on Burn-Injured Amish Patients

“…Dressing changes during conventional burn care are anything but pain free if the patients are not sedated (Kornhaber & Wilson, 2011). Strategies to decrease or eliminate pain during dressing changes, and in turn decrease related psychological trauma, have been the focus of ongoing research (Meaume et al, 2011; Meaume, Téot, Lazareth, Martini, & Bohbot, 2004; Selig et al, 2012; White, 2008). Distraction techniques such as music therapy (Tan, Yowler, Super, & Fratianne, 2010) and video games (Nilsson, Enskär, Hallqvist, & Kokinsky, 2013) to decrease pain during burn care have had some degree of success; patients report lower pain levels.…”

A randomised, controlled, non‐inferiority trial comparing the performance of a soft silicone‐coated wound contact layer (Mepitel One) with a lipidocolloid wound contact layer (UrgoTul) in the treatment of acute wounds

“…Pain severity is a commonly used outcome measure in the clinical evaluation of WCLs. 4,[14][15][16][17][18][19][20][21] In the present study, the main outcome was the frequency and percentage of patients experiencing a pain level <30 mm on a 100 mm VAS at day 3 (V2) immediately after the first allocated dressing had been removed. This pain parameter was selected based on previous research that demonstrates a likelihood of patients recording "moderate" or "severe" pain on a 4-point categorical pain scale scoring above 30 mm on a 100 mm VAS.…”

“…Pain severity is a commonly used outcome measure in the clinical evaluation of WCLs . In the present study, the main outcome was the frequency and percentage of patients experiencing a pain level <30 mm on a 100 mm VAS at day 3 (V2) immediately after the first allocated dressing had been removed.…”

“…Patient eligibility criteria for this study were similar to those used in the RCTs that have previously established the efficacy of Mepitel [14][15][16] and UrgoTul, the reference treatment in the present non-inferiority trial. 4,17,18 Adult patients, aged ≥18 years, were eligible if they presented with an acute wound of traumatic origin (dermabrasion, skin tears, other) or a benign thermal burn (superficial burn without factors that can affect the severity outcome, such as age >60, impairment of vital or functional location or associated lesion, and involving less than 10% of total body surface) requiring the use of dressings. Wound size had to be between 3 and 240 cm 2 and be covered by a maximum of 2 investigational products.…”

Randomized clinical trial of autologous skin cell suspension for accelerating re-epithelialization of split-thickness donor sites

“…The present study was conducted to investigate whether autologous skin cell suspension treatment could promote donor‐site wound healing, reduce morbidities such as pain and itching, and achieve better aesthetic outcomes. An RCT was conducted to compare standard care (non‐occlusive hydrocolloid dressing; Urgotul ® , Laboratories Urgo, Chenôve, France), with and without autologous skin cell treatment.…”